Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
Status:
Active, not recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This is an open-label, two-part, multicenter study to evaluate the safety and tolerability of
DS-8201a in participants with advanced solid malignant tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Daiichi Sankyo Co., Ltd.
Collaborators:
AstraZeneca Daiichi Sankyo Inc. Daiichi Sankyo, Inc.